SecBot SecBot

CTNM

Contineum Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001855175 Biotech & Drug Discovery
$9.67 −0.19 (−1.93%)
Nov 16 4:00 PM ET · prev $9.86
Market cap
$384.0M
Small cap
Consensus
Buy
79% Buy or better · 14 analysts
Median target
$22.00
+128% · range $14.00–30.00
1 year
−13.3%
from $11.15 · Nov 17
30 days
+30.0%
from $7.44
52-week range
$7.08–17.57
−45% from high · low Oct 16
Avg volume 20D
562.3K
Oct 20 spike 2.20M
Short interest
3.70M
≈9.4% of shares · +1.1%
Days to cover
4.2
at average volume
Insider net
−$1.7M
0 buyers · 3 sellers · since Feb 3
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 10 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 9 neutral oldest → newest, height = score
Avg score ·High conf. 7/10

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

  • Feb 3 ▼ 1 insider sell $62.3K at $14.94
  • Feb 11 ▼ 2 insiders sell $12.8K at $16.00
  • Feb 19 to Mar 2 ▼ 4 days of insider sells: $362.3K by 3 insiders, avg $15.68
  • Apr 6 ▼ 1 insider sell $56.0K at $13.43
  • May 1 ▼ 1 insider sell $54.7K at $13.12
  • Jun 1 ▼ 1 insider sell $54.9K at $13.16
  • Jun 30 to Jul 9 ▼ 4 days of insider sells: $984.9K by 3 insiders, avg $16.00
  • Aug 3 ▼ 1 insider sell $40.0K at $16.01
  • Sep 8 ▼ 1 insider sell $41.1K at $16.46
  • Sep 29 Trading halt: Halt Resumed: CTNM, trading resumed after LUDP (Volatility…
  • Sep 30 ▼ Short interest jumps 25.5% to 3.07M
  • Oct 14 ▼ Baird downgrades

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $1.7M.

  • InstitutionsBULLISH

    Q3 2026: 12 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    11 of 14 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +1.1% to 3.70M shares. 4.2 days to cover, ≈9.4% of shares.

  • TrendDOWNTREND

    13% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
FMR LLCDOUBLED2,610,248$35.0M
STATE STREET CORPADD808,514$10.9M
DIMENSIONAL FUND ADVISORS LPADD244,414$3.3M
Nuveen, LLCADD57,736$774.8K
ALPS ADVISORS INCADD43,357$581.9K
RENAISSANCE TECHNOLOGIES LLCNEAR_EXIT15,500$208.0K
BARCLAYS PLCTRIM15,166$203.5K
BNP PARIBAS FINANCIAL MARKETSNEAR_EXIT6,561$88.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 79% rate it Buy or better
Strong Buy5Buy6Hold3Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +128%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 15, 2026Jones Trading
MAINTAIN
MAINTAINBuy
Oct 14, 2026Baird
DOWNGRADE
DOWNGRADENeutral
Sep 28, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Sep 15, 2026Jones Trading
MAINTAIN
MAINTAINBuy
Sep 15, 2026Baird
MAINTAIN
MAINTAINOutperform
Jul 31, 2026RBC Capital
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$1.7M
sold · 3 insiders
DateInsiderTypeValue
Sep 8, 2026
Stengone Carmine N.
CEO and President
Sep 8, 2026
EXERCISE$2.5K
Sep 8, 2026
Stengone Carmine N.
CEO and President
Sep 8, 2026
SELL$41.1K
Aug 3, 2026
Stengone Carmine N.
CEO and President
Aug 3, 2026
EXERCISE$2.5K
Aug 3, 2026
Stengone Carmine N.
CEO and President
Aug 3, 2026
SELL$40.0K
Jul 9, 2026
Lorrain Daniel S.
Chief Scientific Officer
Jul 9, 2026
EXERCISE$25.25
Jul 9, 2026
Lorrain Daniel S.
Chief Scientific Officer
Jul 9, 2026
SELL$400.00
Jul 8, 2026
Stengone Carmine N.
CEO and President
Jul 8, 2026
EXERCISE$2.5K
Jul 8, 2026
Stengone Carmine N.
CEO and President
Jul 8, 2026
SELL$40.0K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.47-$0.54–-$0.39-4.4%$0.00
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
3,696,673
shares short
+1.1%
vs prior settlement
4.2
days to cover
≈9.4%
of shares outstanding
Trading halts
Sep 29, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 11, 2026 Earnings calendar
CTNM Q3 2026 Earnings Scheduled · 2026-11-11
Nov 10, 2026 SEC
Four asset managers added to their CTNM positions in Q3 2026, totaling $577K in net buying, while one seller trimmed…
INST-CLUSTER · Impact 2/10
Nov 6, 2026 SEC
Johnson & Johnson Innovation-JJDC (a J&J subsidiary) filed an amended Schedule 13G disclosing a 5.6% passive stake in…
SC 13G/A · Impact 3/10
Sep 30, 2026 Inst.
FMR LLC · DOUBLED
2,610,248 shares ($35.0M)
Sep 30, 2026 Inst.
STATE STREET CORP · ADD
808,514 shares ($10.9M)
Sep 8, 2026 Insider
Stengone Carmine N. acquired via exercise 2,500 shares
CEO and President @ $1.01 ($2.5K)
Sep 8, 2026 Insider
Stengone Carmine N. sold 2,500 shares
CEO and President @ $16.46 ($41.1K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent

SecBot reports

14 filings · 0 bullish · 0 bearish · 1 mixed · 13 neutral
All CTNM filing & press-release reports (14)